{
    "id": "0759",
    "question": "A 33-year-old woman presents to the clinic for follow-up of her AIDS treatment with highly active anti-retroviral therapy (HAART). She is in good spirits and has been fully compliant with her medications and clinic visits. Other medications include prophylactic co-trimoxazole. Recent blood studies show the following:\nHemoglobin (Hb%)  11 g/dL\nMean corpuscular volume (MCV)  80 fl\nReticulocyte count 0.5%\nErythrocyte count 2 x 106/mm3\nLeucocyte count 700/mm3\nNeutrophils 40%\nPlatelet count 20,000/mm3\nAssays also show a decreased viral DNA and mRNA burden, as well as a significantly diminished viral load. To avoid modifying the effective anti-retroviral therapy, she is started on a \u2018blood improving\u2019 medication. Thirty minutes after the first dose, the patient develops difficulty breathing, severe muscle pain, and vomiting. Her pulse rate is 120/min and the blood pressure is 80/50 mm Hg. Which of the following medications was most likely administered to the patient?",
    "options": {
        "A": "Interleukin 3",
        "B": "Platelet-derived growth factor",
        "C": "Sargramostim",
        "D": "Thrombopoietin"
    },
    "answer": "C",
    "predict": "{\"step_by_step_thinking\": \"To solve this question, we need to analyze the patient's symptoms and lab results to determine which medication is most likely responsible for the adverse reaction. The patient is on highly active anti-retroviral therapy (HAART) for AIDS and has been compliant with her medications and clinic visits. However, she is started on a 'blood improving' medication to avoid modifying her HAART. The patient presents with difficulty breathing, severe muscle pain, vomiting, tachycardia (elevated pulse rate), and hypotension (low blood pressure). These symptoms are indicative of an allergic reaction or anaphylaxis. The patient's lab results show a low platelet count (20,000/mm^3), which is a concern for bleeding disorders. However, the presence of anaphylaxis symptoms suggests a more immediate and severe reaction. The options provided are all medications that stimulate the immune system, but one of them is known to cause severe anaphylaxis and thrombocytosis (an increase in platelet count). A. Interleukin 3 (IL-3) is a growth factor that stimulates the production of white blood cells, but it is not commonly associated with anaphylaxis or thrombocytosis. B. Platelet-derived growth factor (PDGF) is a growth factor that stimulates the production of platelets, but it is not typically associated with anaphylaxis. C. Sargramostim is a granulocyte-macrophage colony-stimulating factor (GM-CSF) analog that stimulates the production of white blood cells, including platelets. It is known to cause severe anaphylaxis and thrombocytosis, making it a likely candidate for the medication responsible for the patient's reaction. D. Thrombopoietin is a hormone that stimulates the production of platelets, but it is not typically associated with anaphylaxis. Given the patient's symptoms of anaphylaxis and thrombocytosis, the most likely medication responsible for the reaction is Sargramostim, a GM-CSF analog that stimulates the production of white blood cells, including platelets.\"} \"answer_choice\": \"C\"",
    "snippets": [],
    "scores": [],
    "execution_time": 61.83887815475464
}